Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 7 W ELECTROLYTES versus TRAVASOL 5 5 W ELECTROLYTES.
Head-to-head clinical analysis: AMINOSYN 7 W ELECTROLYTES versus TRAVASOL 5 5 W ELECTROLYTES.
AMINOSYN 7% W/ ELECTROLYTES vs TRAVASOL 5.5% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids are the building blocks for protein synthesis in the body. This solution provides essential and non-essential amino acids to maintain nitrogen balance and support tissue repair and growth when oral intake is inadequate.
TRAVASOL 5.5% W/ ELECTROLYTES is a parenteral nutritional solution providing amino acids and electrolytes. Amino acids serve as substrates for protein synthesis, while electrolytes maintain osmotic balance and support cellular functions. The solution bypasses gastrointestinal absorption, directly entering the bloodstream.
Intravenous infusion at 1-1.5 g amino acids/kg/day. Typical adult dose: 500 mL of 7% solution (35 g amino acids) infused over 8-12 hours, repeated daily as per nitrogen requirements.
Intravenous infusion: 25-40 mL/kg/day (1.5-2.2 g amino acids/kg/day) as total parenteral nutrition; rate adjusted based on metabolic and clinical response.
None Documented
None Documented
Terminal elimination half-life for the constituent amino acids ranges from 0.5 to 4 hours, depending on the specific amino acid and metabolic state. Clinically, infusion rate should be adjusted to avoid accumulation in renal impairment.
2–3 hours for infused amino acids; clinical context: rapid clearance in normal renal function, prolonged in renal impairment.
Primarily renal. Amino acids are deaminated, and nitrogen is excreted as urea in urine. Biliary/fecal excretion is negligible. Almost 100% of infused amino acids are either metabolized or excreted as urea and other nitrogenous wastes.
Renal, >95% as amino acids and metabolites; negligible biliary/fecal.
Category C
Category C
Amino Acid Solution
Amino Acid Solution